Ernexa Therapeutics Inc. (ERNA) Cash from Investing Activities (2010 - 2026)

Ernexa Therapeutics (ERNA) has 17 years of Cash from Investing Activities data on file, last reported at -$2000.0 in Q1 2026.

• Quarterly Cash from Investing Activities changed N/A year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36000.0 (changed N/A YoY) and the FY2025 annual result came in at -$37000.0, up 89.86% from the prior year.
• Cash from Investing Activities grew to -$2000.0 in Q1 2026, from -$15000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $129000.0 in Q4 2022 to a low of -$249000.0 in Q2 2024.
• A 5-year average of -$44800.0 and a median of -$31000.0 in 2022 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 187.76% in 2022, down 8600.0% in 2022.
• Tracing ERNA's Cash from Investing Activities over 5 years: stood at $129000.0 in 2022, then slumped by 114.73% to -$19000.0 in 2023, then changed by 0.0% to -$19000.0 in 2024, then grew by 21.05% to -$15000.0 in 2025, then soared by 86.67% to -$2000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$2000.0 (Q1 2026), -$15000.0 (Q4 2025), and -$19000.0 (Q3 2024), per Business Quant data.